+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Seborrhoeic Dermatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Seborrhoeic Dermatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Moderate To Severe Atopic Dermatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Moderate To Severe Atopic Dermatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Gout - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Egg Allergy - Pipeline Insight, 2025 - Product Thumbnail Image

Egg Allergy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
RIPK1 Inhibitor - Pipeline Insights, 2025 - Product Thumbnail Image

RIPK1 Inhibitor - Pipeline Insights, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Myositis - Pipeline Insight, 2025 - Product Thumbnail Image

Myositis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Lung Transplant Rejection - Pipeline Insight, 2025 - Product Thumbnail Image

Lung Transplant Rejection - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
P Selectin Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

P Selectin Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025 - Product Thumbnail Image

PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025

  • Report
  • April 2025
  • 400 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more